Literature DB >> 19058149

End-of-life planning and its relevance for patients' and oncologists' decisions in choosing cancer therapy.

Biren Saraiya1, Susan Bodnar-Deren, Elaine Leventhal, Howard Leventhal.   

Abstract

The goal of end-of-life (EoL) planning is to provide individuals with tools to control their financial and healthcare decisions when they are incapacitated. When an elderly patient is diagnosed with advanced cancer, the possible treatment options are palliative care with curative intent or prolongation of life or palliative care only. Treatment of cancer in elderly patients creates a significant array of monetary and symptom burdens. The question is whether advance care planning, part of EoL planning, allows patients' families and communities to control and reduce these burdens. Although the number of patients completing advance directives has increased in recent years, there are multiple barriers to the implementation of patients' wishes, such as limited knowledge of patient wishes by proxy and physician and inadequate communication regarding prognosis. In this article, the authors propose that improvements in patient decision making and clinical practice can reduce the burden of symptoms for patients if clinicians gain a better understanding of patients' models and expectations respecting the longer term consequences of diagnosis and treatment. This understanding can arise from improved information exchange and constant updating of the information as the disease and treatment evolves. Clinicians also need better prognostication tools and better training in effective communication skills to elicit patient goals and to make appropriate recommendations.

Entities:  

Mesh:

Year:  2008        PMID: 19058149      PMCID: PMC2606925          DOI: 10.1002/cncr.23946

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

1.  End-of-life care directives among African Americans: lessons learned--a need for community-centered discussion and education.

Authors:  C M Waters
Journal:  J Community Health Nurs       Date:  2000       Impact factor: 0.974

Review 2.  Measurement and impact of comorbidity in older cancer patients.

Authors:  M Extermann
Journal:  Crit Rev Oncol Hematol       Date:  2000-09       Impact factor: 6.312

Review 3.  Short-term cost for long-term benefit: time preference and cancer control.

Authors:  Gretchen B Chapman
Journal:  Health Psychol       Date:  2005-07       Impact factor: 4.267

4.  Patient time costs associated with cancer care.

Authors:  K Robin Yabroff; William W Davis; Elizabeth B Lamont; Angela Fahey; Marie Topor; Martin L Brown; Joan L Warren
Journal:  J Natl Cancer Inst       Date:  2007-01-03       Impact factor: 13.506

5.  Prognostic disclosure to patients with cancer near the end of life.

Authors:  E B Lamont; N A Christakis
Journal:  Ann Intern Med       Date:  2001-06-19       Impact factor: 25.391

6.  Advance directives for seriously ill hospitalized patients: effectiveness with the patient self-determination act and the SUPPORT intervention. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment.

Authors:  J Teno; J Lynn; N Wenger; R S Phillips; D P Murphy; A F Connors; N Desbiens; W Fulkerson; P Bellamy; W A Knaus
Journal:  J Am Geriatr Soc       Date:  1997-04       Impact factor: 5.562

7.  Risks and benefits of phase 1 oncology trials, 1991 through 2002.

Authors:  Elizabeth Horstmann; Mary S McCabe; Louise Grochow; Seiichiro Yamamoto; Larry Rubinstein; Troy Budd; Dale Shoemaker; Ezekiel J Emanuel; Christine Grady
Journal:  N Engl J Med       Date:  2005-03-03       Impact factor: 91.245

8.  Patients preferences in chemotherapy for advanced non-small-cell lung cancer.

Authors:  Takashi Hirose; Naoya Horichi; Tohru Ohmori; Sohjiroh Kusumoto; Tomohide Sugiyama; Takao Shirai; Tetsuji Ozawa; Tsukasa Ohnishi; Mitsuru Adachi
Journal:  Intern Med       Date:  2005-02       Impact factor: 1.271

9.  Inconsistency over time in the preferences of older persons with advanced illness for life-sustaining treatment.

Authors:  Terri R Fried; John O'Leary; Peter Van Ness; Liana Fraenkel
Journal:  J Am Geriatr Soc       Date:  2007-07       Impact factor: 5.562

10.  Proxy perspectives regarding end-of-life care for persons with cancer.

Authors:  Marie Bakitas; Tim A Ahles; Karen Skalla; Frances C Brokaw; Ira Byock; Brett Hanscom; Kathleen Doyle Lyons; Mark T Hegel
Journal:  Cancer       Date:  2008-04-15       Impact factor: 6.860

View more
  6 in total

1.  Aging in the context of cancer prevention and control : perspectives from behavioral medicine.

Authors:  Keith M Bellizzi; Karen M Mustian; Deborah J Bowen; Barbara Resnick; Suzanne M Miller
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

2.  Patient-physician discordance in goals of care for patients with advanced cancer.

Authors:  S L Douglas; B J Daly; N J Meropol; A R Lipson
Journal:  Curr Oncol       Date:  2019-12-01       Impact factor: 3.677

3.  The process of advance care planning in HCT candidates and proxies: self-efficacy, locus of control, and anxiety levels.

Authors:  Katharine E Duckworth; Allison M Forti; Gregory B Russell; Seema Naik; David Hurd; Richard P McQuellon
Journal:  Am J Hosp Palliat Care       Date:  2013-08-13       Impact factor: 2.500

4.  Transition from curative to palliative care in cancer.

Authors:  Jaspreet Kaur; Bidhu K Mohanti
Journal:  Indian J Palliat Care       Date:  2011-01

5.  Advance care planning among hematopoietic cell transplant patients and bereaved caregivers.

Authors:  E T Loggers; S Lee; K Chilson; A L Back; S Block; F R Loberiza
Journal:  Bone Marrow Transplant       Date:  2014-07-28       Impact factor: 5.483

6.  The PREPARE for Your Care program increases advance care planning engagement among diverse older adults with cancer.

Authors:  Sarah S Nouri; Deborah E Barnes; Ying Shi; Aiesha M Volow; Nikita Shirsat; Anne L Kinderman; Heather A Harris; Rebecca L Sudore
Journal:  Cancer       Date:  2021-06-02       Impact factor: 6.921

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.